Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DFTX Definium Therapeutics

Market Closed 03-27 16:00:00 EDT

17.88

-1.06

-5.60%

盘后17.88

+0.000.00%

19:42 EDT

High18.84	Low17.66	Vol1.74M
Open18.83	D1 Closing18.94	Amplitude6.23%
Mkt Cap1.78B	Tradable Cap1.68B	Total Shares99.70M
T/O31.41M	T/O Rate1.86%	Tradable Shares93.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":17.88,"timestamp":1774641600000,"preClose":18.94,"halted":0,"volume":1743351,"hourTrading":{"tag":"盘后","latestPrice":17.88,"preClose":17.88,"latestTime":"19:42 EDT","volume":30968,"amount":553806.87,"timestamp":1774654925627,"change":0,"changeRate":0,"amplitude":0.019575},"delay":0,"changeRate":-0.05596620908130952,"floatShares":93736700,"shares":99698129,"eps":-2.059999,"marketStatus":"Market Closed","change":-1.06,"latestTime":"03-27 16:00:00 EDT","open":18.83,"high":18.84,"low":17.66,"amount":31405139.831538,"amplitude":0.062302,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.059999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":18.94,"preHourTrading":{"tag":"盘前","latestPrice":18.65,"preClose":18.94,"latestTime":"09:29 EDT","volume":2667,"amount":49849.105026000005,"timestamp":1774618199903,"change":-0.29,"changeRate":-0.015312,"amplitude":0.022508},"postHourTrading":{"tag":"盘后","latestPrice":17.88,"preClose":17.88,"latestTime":"19:42 EDT","volume":30968,"amount":553806.87,"timestamp":1774654925627,"change":0,"changeRate":0,"amplitude":0.019575},"volumeRatio":0.972165,"impliedVol":0.8518,"impliedVolPercentile":0.5918},"requestUrl":"/m/hq/s/DFTX/wiki","defaultTab":"wiki","newsList":[{"id":"2623917338","title":"A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2623917338","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623917338?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:09","pubTimestamp":1774724949,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) is back in focus after recent communications around its April Investor & Analyst Day, where management plans to spotlight late stage DT120 ODT data timelines in major depressive disorder and generalized anxiety disorder.\nSee our latest analysis for Definium Therapeutics.\nDefinium Therapeutics’ recent Investor & Analyst Day spotlight and earlier name change have arrived after a strong run, with a 90 day share price return of 36.91% and a very large 3 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-as-investor-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-as-investor-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","SSI","DFTX","ODT"],"gpt_icon":0},{"id":"2622859009","title":"Definium Therapeutics to host Investor and Analyst Day; DT120 ODT Phase 3 program to be highlighted","url":"https://stock-news.laohu8.com/highlight/detail?id=2622859009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622859009?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522843,"startTime":"0","endTime":"0","summary":"Definium will host an Investor & Analyst Day in New York on April 22, 2026.The event is scheduled for 10 AM to 12 PM EDT.Sessions will be led by Definium’s executive leadership team and external speakers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8ggRt0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2621767464","title":"A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2621767464","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621767464?lang=en_us&edition=fundamental","pubTime":"2026-03-21 18:09","pubTimestamp":1774087778,"startTime":"0","endTime":"0","summary":"Recent performance snapshot for Definium Therapeutics (DFTX)\nDefinium Therapeutics (NasdaqGS:DFTX) has drawn attention after a past 3 months total return of 44.9% and a 1 year total return above 100%. This has prompted closer scrutiny of its clinical stage risk and valuation.\nSee our latest analysis for Definium Therapeutics.\nThe recent 90 day share price return of 44.9% and very large 3 year total shareholder return suggest momentum has been building, even though the latest 1 day move showed...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-after-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2618794597","title":"Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618794597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618794597?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:20","pubTimestamp":1773224408,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Definium Therapeutics (DFTX – Research Report), Integer Holdings ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-integer-holdings-itgr-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-integer-holdings-itgr-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4588","LU0566484027.USD","BK4585","LU1559883803.SGD","LU1169590202.USD","BK4082","LU0757428866.USD","LU0128526141.USD","ITGR","BK4007","EWTX","LU0029874061.USD","BK4581","HCSG","LABU","LU1169589451.USD","XLV","XBI","LU1815336091.USD","BK4137","BK4539"],"gpt_icon":0},{"id":"2618717056","title":"Definium Therapeutics issues inducement equity grants of 134,540 options and 34,500 PSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618717056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618717056?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086476,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement equity awards to four newly hired non-executive employees, consisting of options for 134,540 common shares and 34,500 performance share units  at target. The options carry an exercise price equal to the closing share price on each grant date and vest over four years, with 25% vesting after one year. The PSUs vest on the third anniversary of the grant date, subject to continued service. Earned PSUs can range from 0% to 200% of target based on performance over a three-year period.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL3ffJ94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"1132686136","title":"Stock Track | Definium Therapeutics Soars 5.24% Intraday on Analyst Buy Rating and $26 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1132686136","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132686136?lang=en_us&edition=fundamental","pubTime":"2026-03-04 04:24","pubTimestamp":1772569464,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' stock surged 5.24% during intraday trading on Tuesday, following a positive analyst update.The movement comes after Evercore ISI analyst Gavin Clark-Gartner maintained a Buy...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"gpt_icon":0},{"id":"2616348316","title":"Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616348316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616348316?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:16","pubTimestamp":1772529373,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $26.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"gpt_icon":0},{"id":"2616253358","title":"Definium Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616253358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616253358?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:13","pubTimestamp":1772460780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 09:13 ET (14:13 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2616331829","title":"Definium Therapeutics (DFTX) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331829?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:57","pubTimestamp":1772452651,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Definium Therapeutics today and set a price target of $70.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2616031849","title":"Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2616031849","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616031849?lang=en_us&edition=fundamental","pubTime":"2026-03-01 05:25","pubTimestamp":1772313957,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder.\nThe company is approaching pivotal phase III readouts across multiple late stage trials and has launched a new phase II study in autism spectrum disorder.\nDefinium is also increasing its commercial readiness by expanding leadership and building operational infrastructure as it moves toward a potential launch phase.\n\nFor investors watching NasdaqGS:DFTX, this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-advances-dt120-odt-as-trials-and-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-advances-dt120-odt-as-trials-and-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DFTX","ODT","BK4007"],"gpt_icon":0},{"id":"2614758853","title":"Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614758853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614758853?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:39","pubTimestamp":1772195968,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Definium Therapeutics, with a price target of $25.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2614875518","title":"Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2614875518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614875518?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:45","pubTimestamp":1772178357,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham reiterated a Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","SSI","DFTX"],"gpt_icon":0},{"id":"2614074658","title":"Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614074658","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614074658?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:00","pubTimestamp":1772143256,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryDefinium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of 50 cents per share for the quarte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM3FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614079000","title":"Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079000?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:36","pubTimestamp":1772141769,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL4Bs3Mh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614759880","title":"Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614759880","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614759880?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:03","pubTimestamp":1772139813,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.46) by 7.76 percent. This is a 21.95 percent decrease over losses of $(0.41) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50908815/definium-therapeutics-q4-eps-0-50-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2614075616","title":"Definium Therapeutics FY 2025 R&D expenses rise 80.2% to USD 117.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075616?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:02","pubTimestamp":1772139758,"startTime":"0","endTime":"0","summary":"Definium Therapeutics  reported a FY 2025 net loss of USD 183.8 million and a loss from operations of USD 166.3 million, as R&D expenses rose to USD 117.7 million  and G&A expenses increased to USD 48.6 million . Interest income was USD 11.0 million in FY 2025, while interest expense was USD 5.5 million. Cash, cash equivalents and investments totaled USD 411.6 million as of Dec. 31, 2025, and total assets were USD 440.1 million. On the business side, Definium Therapeutics said its Phase 3 MDD trial Emerge is fully enrolled  with topline data anticipated in late Q2 2026, while Phase 3 GAD trial Voyage was about 80% enrolled with topline data expected in early Q3 2026 and no enrollment increase required after a blinded sample size re-estimation. The company also said it initiated a Phase 2a open-label study of DT402  in adults with autism spectrum disorder in Q4 2025, with initial data anticipated in 2026. Definium Therapeutics completed an equity financing in Q4 2025 raising about USD 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLbjvNdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614753040","title":"Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614753040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614753040?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1G6HGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2614071678","title":"Definium Therapeutics - $411.6 Million in Cash, Cash Equivalents and Investments as of December 31, 2025 Expected to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071678?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1G6HGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2614046087","title":"JonesTrading Remains a Buy on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046087?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:45","pubTimestamp":1772009132,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $61.00. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2613671642","title":"Definium Therapeutics Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2613671642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613671642?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:22","pubTimestamp":1771935720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 07:22 ET (12:22 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":0.0148},{"period":"3month","weight":0.3691},{"period":"6month","weight":0.6757},{"period":"1year","weight":1.7807},{"period":"ytd","weight":0.3353}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.060392},{"month":4,"riseRate":0.75,"avgChangeRate":0.007711},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002468},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction